Article

Sitagliptin May Be a Diabetes Preventative As Well

Prediabetic rats treated with sitagliptin not only experienced lower glucagon and higher insulin levels, but a redistribution of body fat.

Researchers seeking ways to prevent prediabetes from progressing to diabetes believe that treatment with sitagliptin might be effective.

A study published in the March 2011 issue of Experimental Biology and Medicine by researchers from the Department of Nutrition at Case Western Reserve University highlights these efforts. Sitagliptin works by boosting the GLP-1, the intestinal factor that increases insulin output while also decreasing glucagon output.

They used an animal model with prediabetes, the SHROB rat, which was developed at Case Western Reserve University in the 1970s. These rats are extremely obese and have normal glucose after fasting but high glucose after a meal, like prediabetic humans. Also like prediabetic humans, they have excessive levels of glucagon.

The prediabetic rats were divided into three groups and treated with either a placebo, sitagliptin, or another older diabetes medication, glyburide, which acts by boosting the production of insulin by the pancreas. Sitagliptin and glyburide were equally effective in lowering glucose levels after a meal. Surprisingly, only sitagliptin raised the total output of insulin by the pancreas and only sitagliptin lowered glucagon to normal levels.

Neither of the diabetes medications had any effect on body weight, total body fat or food intake. This matches studies in humans, which show no loss or gain of weight from these drugs. But differences appeared when the distribution of body fat was examined. Compared to the older drug glyburide, sitagliptin caused a redistribution of body fat from the abdominal fat deposits to deposits under the skin. Lowering the proportion of fat stored within the abdomen has a number of favorable effects in diabetes and for cardiovascular risk factors. This is the first time that sitagliptin has been found to affect fat distribution, and the cellular basis for this change is an open question.

Group leader Paul Ernsberger, PhD, says, "These animal studies suggest that sitagliptin should be tested in the clinic as a possible diabetes-preventing medication. It may act to shore up the function of the pancreas, which deteriorates during the onset of diabetes." Co-investigator Richard J. Koletsky, MD. says "Sitagliptin's effects on enhancing post prandial insulin secretion and decreasing glucagon secretion offer new pharmacologic interventions to combat diabetes and potentially delay and even prevent its onset."

Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "this animal model study by Ernsberger and colleagues suggests that sitagliptin can slow the onset of diabetes. Of great interest is the finding that this drug can redistribute body fat from the abdomen to deposits under the skin."

Source: Society for Experimental Biology and Medicine

Related Videos
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
© 2024 MJH Life Sciences

All rights reserved.